Discover 1,003 paid clinical trials in Saint Paul, Minnesota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,003
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
for
Smoldering Plasma Cell Myeloma
Location: Saint Paul MN, Woodbury MN, Maplewood MN,
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All
Age: 18+
Code: NCT03937635
Phase3, Recruiting
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Saint Paul MN, Minneapolis MN, Edina MN,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT05642572
Phase2, Recruiting
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
for
Renal Pelvis and Ureter Urothelial Carcinoma
Location: Saint Paul MN, Woodbury MN, Maplewood MN,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04628767
Phase2, Phase3, Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Location: Saint Paul MN, Maplewood MN, Minneapolis MN, Edina MN,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04181060
Phase3, Recruiting
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
for
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Location: Saint Paul MN, Woodbury MN, Maplewood MN,
Sponsor: NRG Oncology
Sex: All
Age: 45 - 70
Code: NCT05080673
Recruiting
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
for
Metastatic Malignant Neoplasm in the Liver,
Location: Saint Paul MN, Woodbury MN, Maplewood MN,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT05040360
Phase2, Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors